MX377733B - Tratamiento de enfermedad de alzheimer leve y moderada. - Google Patents
Tratamiento de enfermedad de alzheimer leve y moderada.Info
- Publication number
- MX377733B MX377733B MX2015003732A MX2015003732A MX377733B MX 377733 B MX377733 B MX 377733B MX 2015003732 A MX2015003732 A MX 2015003732A MX 2015003732 A MX2015003732 A MX 2015003732A MX 377733 B MX377733 B MX 377733B
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- mild
- disease
- moderate alzheimer
- phenoxy
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261710229P | 2012-10-05 | 2012-10-05 | |
| PCT/US2013/062964 WO2014055588A1 (en) | 2012-10-05 | 2013-10-02 | Treatment of mild and moderate alzheimer's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015003732A MX2015003732A (es) | 2015-09-23 |
| MX377733B true MX377733B (es) | 2025-03-11 |
Family
ID=49354960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015003732A MX377733B (es) | 2012-10-05 | 2013-10-02 | Tratamiento de enfermedad de alzheimer leve y moderada. |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2903606A1 (enExample) |
| JP (2) | JP6566868B2 (enExample) |
| KR (1) | KR20150064743A (enExample) |
| CN (2) | CN110292638A (enExample) |
| AU (2) | AU2013327450B2 (enExample) |
| BR (1) | BR112015007641A8 (enExample) |
| CA (1) | CA2886785C (enExample) |
| EA (1) | EA201590687A1 (enExample) |
| HK (1) | HK1207004A1 (enExample) |
| IL (1) | IL237730B (enExample) |
| IN (1) | IN2015DN03734A (enExample) |
| MX (1) | MX377733B (enExample) |
| NZ (2) | NZ739521A (enExample) |
| SG (2) | SG10201702648YA (enExample) |
| WO (1) | WO2014055588A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019190822A1 (en) | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| WO2019190823A1 (en) * | 2018-03-28 | 2019-10-03 | Vtv Therapeutics Llc | Pharmaceutically acceptable salts of [3-(4- {2-butyl-1-[4-(4-chlorophenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine |
| EP3864008A1 (en) | 2018-10-10 | 2021-08-18 | vTv Therapeutics LLC | Metabolites of [3-(4-{2-butyl-l-[4-(4-chloro-phenoxy)-phenyl]-lh-imidazol-4-yl } -phen ox y)-prop yl] -diethyl-amine |
| WO2020086388A1 (en) * | 2018-10-22 | 2020-04-30 | Vtv Therapeutics Llc | Glucokinase activator compositions for the treatment of cognitive impairment |
| JP7327788B2 (ja) * | 2019-08-06 | 2023-08-16 | 学校法人福岡大学 | 糖化産物生成抑制剤及び医薬組成物 |
| CN114716551B (zh) * | 2021-11-12 | 2023-01-24 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101613321A (zh) * | 2002-03-05 | 2009-12-30 | 特兰斯泰克制药公司 | 抑制配体与高级糖化终产物受体相互作用的单和双环吡咯衍生物 |
| WO2005000295A1 (en) * | 2003-05-20 | 2005-01-06 | Transtech Pharma, Inc. | Rage antagonists as agents to reverse amyloidosis and diseases associated therewith |
| EP1707203A1 (en) * | 2005-04-01 | 2006-10-04 | Bioprojet | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands |
| JP2010523559A (ja) * | 2007-04-05 | 2010-07-15 | トランス テック ファーマ，インコーポレイテッド | ［３−（４−｛２−ブチル−１−［４−（４−クロロ−フェノキシ）−フェニル］−１ｈ−イミダゾール−４−イル｝−フェノキシ）−プロピル］−ジエチルアミンの結晶形態 |
| CN101663280A (zh) * | 2007-04-05 | 2010-03-03 | 转化技术制药公司 | [3-(4-{2-丁基-1-[4-(4-氯-苯氧基)-苯基]-1h-咪唑-4-基}-苯氧基)-丙基]-二乙基-胺的晶型ⅰ和ⅱ |
| US20100254983A1 (en) * | 2007-06-07 | 2010-10-07 | Ann Marie Schmidt | Uses of rage antagonists for treating obesity and related diseases |
| US20090221554A1 (en) * | 2008-02-28 | 2009-09-03 | Zenyaku Kogyo Kabushiki Kaisha | Method of treating cognitive impairment |
| EP2638052B1 (en) * | 2010-11-08 | 2017-03-22 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
-
2013
- 2013-10-02 KR KR1020157011366A patent/KR20150064743A/ko not_active Ceased
- 2013-10-02 CN CN201910466681.3A patent/CN110292638A/zh active Pending
- 2013-10-02 EP EP13776676.2A patent/EP2903606A1/en not_active Withdrawn
- 2013-10-02 NZ NZ739521A patent/NZ739521A/en unknown
- 2013-10-02 EA EA201590687A patent/EA201590687A1/ru unknown
- 2013-10-02 MX MX2015003732A patent/MX377733B/es active IP Right Grant
- 2013-10-02 NZ NZ705813A patent/NZ705813A/en unknown
- 2013-10-02 AU AU2013327450A patent/AU2013327450B2/en active Active
- 2013-10-02 IN IN3734DEN2015 patent/IN2015DN03734A/en unknown
- 2013-10-02 SG SG10201702648YA patent/SG10201702648YA/en unknown
- 2013-10-02 CN CN201380051206.0A patent/CN104703592A/zh active Pending
- 2013-10-02 BR BR112015007641A patent/BR112015007641A8/pt active Search and Examination
- 2013-10-02 WO PCT/US2013/062964 patent/WO2014055588A1/en not_active Ceased
- 2013-10-02 SG SG11201502210VA patent/SG11201502210VA/en unknown
- 2013-10-02 JP JP2015535750A patent/JP6566868B2/ja active Active
- 2013-10-02 CA CA2886785A patent/CA2886785C/en active Active
- 2013-10-02 HK HK15107776.8A patent/HK1207004A1/xx unknown
-
2015
- 2015-03-12 IL IL237730A patent/IL237730B/en active IP Right Grant
-
2018
- 2018-05-16 AU AU2018203434A patent/AU2018203434A1/en not_active Abandoned
-
2019
- 2019-05-23 JP JP2019096786A patent/JP6894940B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6566868B2 (ja) | 2019-08-28 |
| AU2013327450B2 (en) | 2018-07-12 |
| SG10201702648YA (en) | 2017-04-27 |
| AU2013327450A1 (en) | 2015-05-14 |
| IL237730B (en) | 2018-10-31 |
| CN104703592A (zh) | 2015-06-10 |
| NZ739521A (en) | 2019-06-28 |
| CA2886785A1 (en) | 2014-04-10 |
| KR20150064743A (ko) | 2015-06-11 |
| SG11201502210VA (en) | 2015-04-29 |
| WO2014055588A1 (en) | 2014-04-10 |
| CA2886785C (en) | 2022-06-07 |
| CN110292638A (zh) | 2019-10-01 |
| NZ705813A (en) | 2018-02-23 |
| JP2019163301A (ja) | 2019-09-26 |
| IN2015DN03734A (enExample) | 2015-09-18 |
| BR112015007641A8 (pt) | 2018-04-03 |
| HK1207004A1 (zh) | 2016-01-22 |
| EP2903606A1 (en) | 2015-08-12 |
| MX2015003732A (es) | 2015-09-23 |
| JP2015535850A (ja) | 2015-12-17 |
| EA201590687A1 (ru) | 2015-09-30 |
| BR112015007641A2 (pt) | 2017-07-04 |
| JP6894940B2 (ja) | 2021-06-30 |
| AU2018203434A1 (en) | 2018-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ716487A (en) | Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide | |
| UA112317C2 (uk) | Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину | |
| EA201692280A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201190235A1 (ru) | Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750 | |
| EA201492281A1 (ru) | Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar) | |
| UA113051C2 (xx) | Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів | |
| EA201190217A1 (ru) | Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение | |
| BR112014023384A2 (pt) | inibidores de bace de di-hidro-tiazina e di-hidro-oxazina espirocíclicos, e composições e usos dos mesmos | |
| UA113538C2 (xx) | Фторметил-5,6-дигідро-4h-$1,3]оксазини | |
| MX377733B (es) | Tratamiento de enfermedad de alzheimer leve y moderada. | |
| WO2013061004A8 (fr) | Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines | |
| EA201590735A1 (ru) | 2-фенил-5-гетероциклил-тетрагидро-2h-пиран-3-аминовые соединения для применения в лечении диабета и связанных с ним расстройств | |
| PH12015502365A1 (en) | Bace1 inhibitors | |
| EA201591180A1 (ru) | Составы ингибитора lfa-1 | |
| EA201790253A1 (ru) | Ингибиторы альдостеронсинтазы | |
| EA201890532A1 (ru) | Новые аннелированные бензамиды | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| PH12015500012B1 (en) | Benzodioxole derivative and preparation method and use thereof | |
| EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
| EA201390327A1 (ru) | Гетероциклильные соединения в качестве лигандов гистаминовых hрецепторов | |
| MX2015006807A (es) | Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas. | |
| MX2013011561A (es) | Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| MX376431B (es) | Derivado de piperidina y sus métodos de uso. | |
| UA103803C2 (en) | Use of 1-methoxycarbonylmethyl-7-bromo-5-phenyl-3-arylamino-1,2-dihydro-3h-1,4-benzodiazepine-ones as analgetic agents | |
| UA112586C2 (uk) | Похідні бензімідазолпроліну |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: AK STEEL PROPERTIES, INC.* Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC |
|
| GB | Transfer or rights |
Owner name: VTV THERAPEUTICS LLC |
|
| HC | Change of company name or juridical status |
Owner name: AK STEEL PROPERTIES, INC.* |
|
| FG | Grant or registration |